Prophylactic Ruxolitinib for Cytokine Release Syndrome (CRS) in Relapse/Refractory (R/R) AML Patients Treated with Flotetuzumab
2020
-
Correction
-
Source
-
Cite
-
Save
0
References
2
Citations
NaN
KQI